Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma

Evaluating the Safety and Efficacy of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma

The purpose of this study is to evaluate the safety and efficacy of targeted cryoablation therapy for hepatic carcinoma.

A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 10-6-10minutes.

Inclusion Criteria:

• Diagnosis of liver cancer based on histology or the current accepted radiological measures.
• Single Tumor size ≤5.0 cm in greatest diameter, or multiple tumor number≤3 and each tumor size≤ 3cm.
• Life expectancy: Greater than 3 months.
• Patients' liver function is Child-pugh A or B.
• Ability to understand the study protocol and a willingness to sign a written informed consent document.
• Unable to receive operative surgery.

Exclusion Criteria:

• Patients with other primary tumor except liver cancer.
• History of coagulation disorders or anemia.